用于转移性去势抵抗性前列腺癌的新药。
New Drug for Metastatic Castration-Resistant Prostate Cancer.
机构信息
Diane S. Aschenbrenner is a former member of the faculty at Notre Dame of Maryland University and the Johns Hopkins University School of Nursing. She coordinates Drug Watch :
出版信息
Am J Nurs. 2022 Jul 1;122(7):27. doi: 10.1097/01.NAJ.0000842248.30975.3f.
Abstract
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have received androgen receptor pathway inhibition and taxane-based chemotherapy.
摘要
普维妥（镥 177 标记的维替泊肽四聚体）已获批用于治疗已接受雄激素受体通路抑制和紫杉烷类化疗的前列腺特异性膜抗原阳性转移性去势抵抗性前列腺癌的成年患者。
Zotero 插件